Key result
Whole-heart beta-adrenoceptor density early after myocardial infarction was significantly associated with the long-term incidence of congestive heart failure (HR 0.29; 95% CI 0.15-0.58; P<0.001).
Why the study?
Is reduced myocardial beta-adrenoceptor density measured early after a first myocardial infarction associated with long-term incidence of congestive heart failure?
Cohort (n=61)
Is reduced myocardial beta-adrenoceptor density measured early after a first myocardial infarction associated with long-term incidence of congestive heart failure?
Hazard Ratio: 0.29 (95% CI 0.15–0.58)
Absolute Event Rate: 57% vs 9%
p-value: p=<0.001
Reduced myocardial beta-adrenoceptor density measured by PET early after a first myocardial infarction is a strong independent predictor of long-term congestive heart failure incidence.
AIMS: Adverse left ventricular (LV) remodelling after myocardial infarction (MI) frequently leads to congestive heart failure (CHF). We have previously shown that myocardial beta-adrenoceptor density (beta-ARD) is reduced soon after acute MI and correlates with LV dilatation in the short term. The aim of the present study was to determine whether myocardial beta-ARD measured early after MI was associated with progression to CHF in the long term. METHODS AND RESULTS: We prospectively included 61 consecutive patients (mean age, 52 +/- 11 years, 10 female) in whom MI was the first manifestation of coronary artery disease. Two to 4 weeks after MI, patients underwent positron emission tomography with S-[(11)C]CGP 12177 to measure beta-ARD and (15)O-labelled water to measure myocardial blood flow and coronary flow reserve. Patients were followed-up for a median of 12.7 years (interquartile range, 6.5-13.7 years) and incidence of CHF was recorded. Eleven patients (18%) developed CHF during follow-up. They had lower beta-ARD compared with those who did not (5.35 vs. 6.49 pmol/g, P < 0.001). In patients with myocardial beta-ARD < or =5.57 pmol/g, 10-year CHF incidence rates were higher than in patients with beta-ARD >5.57 pmol/g (57% vs. 9%, P < 0.001). In a Cox regression model, only whole-heart beta-ARD [hazard ratio (HR) 0.29; 95% confidence interval (CI), 0.15-0.58, P < 0.001] and beta-ARD in remote myocardium (HR 0.32; 95% CI, 0.16-0.61, P = 0.001) were significantly associated with the incidence of CHF at follow-up. CONCLUSION: Reduced myocardial beta-ARD early after MI is associated with the incidence of CHF on long-term follow-up.
No takes yet. Share an insight, caveat, or question.
Gaemperli et al. (2010) conducted a cohort in Myocardial infarction (n=61). Myocardial beta-adrenoceptor density (beta-ARD) ≤5.57 pmol/g vs. beta-ARD >5.57 pmol/g was evaluated on Incidence of congestive heart failure (HR 0.29, 95% CI 0.15-0.58, p=<0.001). Whole-heart beta-adrenoceptor density early after myocardial infarction was significantly associated with the long-term incidence of congestive heart failure (HR 0.29; 95% CI 0.15-0.58; P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: